soothe

Joining the Soothe Study







While there are therapies available to treat eozema, many people still struggle to achieve itch relief. This clinical research study is investigating an innovative topical therapy that hopes to reduce itch in adults struggling with persistent mild to moderate eozema.

Sign up to connect with a TrialSpark nurse and learn more

Visit: eczematrial.org/start

Email: soothe.eczema@trialspark.com

Call: +1 (646) 440-1454

Scan QR Code:



Brought to you by:

TrialSpark

eczematrial.org/start

Benefits of participating in this study

Qualified participants will receive access to this newly developed investigational topical therapy, or placebo, for eczema related itch.*

Help Research Future Treatments:

All the results and outcomes of your participation will provide detailed insights into the potential of future treatment options.

Basic Enrollment Process:

A simple 4-step enrollment process helps improve transparency and gives patients access to full administrative support from their Nurse Enrollment Specialist and clinical specialists.

Care from Board Certified Specialists:

Local healthcare experts will monitor your individual progress for the duration of the study.

Eligibility Requirements

- Men and women 18 years or older
- Diagnosis of eczema for at least 12 months
- Persistent itch related to eczema (pruritus)

What does participation look like?

Participation in the study will last 12-weeks in total and consists of three stages:

Screening (28-days)

If you are interested in the Soothe study after completing a patient application and pre-screening, you will review and sign a consent form to make an educated decision about participation. The study doctor also performs final assessments to confirm your eligibility to participate.

Treatment (28-days)

The study medication is being evaluated to determine the safety and effectiveness in reducing eczema-related itch. Patients will receive a topical gel to apply twice daily and monitored for safety and study progress. Certain study visits will be discussed prior to participation and include: physical exams, electrocardiograms (ECGs), blood and urine samples, skin assessments and other tests and assessments conducted at the study site. **

Follow-up (28-days)

After concluding the treatment period, the study doctor will conduct a follow up visit and debrief you 28-days after the last topical application to thoroughly monitor and evaluate the safety, effectiveness, tolerability and more.

*Additional eligibility criteria will be assessed by the study doctor or staff during the screening process prior to being enrolled in the study and receiving any investigational medication. Not all individuals will qualify to participate.

**Neither you nor the study team will know the treatment assignment but there is a 25% chance you receive the placebo.